Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 7th International Workshop on CAR-T and Bispecifics (iwCAR-T) took place in Miami, FL, on April 11-13, 2025, bringing together leading clinical researchers to discuss the latest advances in CAR therapies and bispecific antibodies.
The iwCAR-T and bispecifics 2025 Workshop was supported by Genetech, Johnson & Johnson, Kite, Bristol Myers Squibb, A2 BIO, Galápagos, Miltenyi Biomedicine, Caribou Biosciences, nkarta, Novartis, Legend Biotech, Immatics, Autolus, Biontech and Iovance biotherapeutics. Supporters have no influence over the production of content.
iwCAR-T 2025
The 7th International Workshop on CAR-T and bispecifics
11–13 April 2025 | Miami, FL
The 7th International Workshop on CAR-T and Bispecifics (iwCAR-T) took place in Miami, FL, on April 11-13, 2025, bringing together leading clinical researchers to discuss the latest advances in CAR therapies and bispecific antibodies.
The iwCAR-T and bispecifics 2025 Workshop was supported by Genetech, Johnson & Johnson, Kite, Bristol Myers Squibb, A2 BIO, Galápagos, Miltenyi Biomedicine, Caribou Biosciences, nkarta, Novartis, Legend Biotech, Immatics, Autolus, Biontech and Iovance biotherapeutics. Supporters have no influence over the production of content.
View all videos
Explore roundtable discussions
View all videos
T-cell engagers and CARs in CLL
Optimizing liso-cel in CLL: sequencing and combination strategies
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Coming soon
Why bispecific antibodies may be the path forward in CLL
Alexey Danilov City of Hope, Duarte, CA, United States
CAR-T in ALL
Obecabtagene autoleucel: what have we learned from the FELIX study?
Claire Roddie University College London, London, United Kingdom
CAR T-cell therapy in B-cell ALL
Bijal Shah Moffitt Cancer Center, Tampa, FL, United States
CD19/CD22 CAR-T
Noelle Frey The University of Pennsylvania, Perlman School of Medicine, Philadelphia, PA, United States
coming soon
SCRI‐CAR19 with CD19 T‐APC to prolong CAR-T cell persistence
Rebecca Gardner St. Jude Children's Research Hospital, Memphis, TN, United States
Improving clinical activity of CD5 CAR-T in T-ALL
Maksim Mamonkin Baylor College of Medicine, Houston, TX, United States
CAR therapy for autoimmune diseases
Frontiers in CAR T-cell therapy for autoimmune diseases
David Porter University of Pennsylvania, Philadelphia, PA, United States
Coming soon
Early experience with the in vivo expanding anti-CD19 CAR-T, BMS-986353, for autoimmunity
Lazaros Lekakis Sylvester Myeloma Institute, Miami, FL, United States
CD19 CAR NK-cell therapy for B-cell mediated autoimmune disease
David Shook Nkarta, Inc, South San Francisco, CA, United States
CAR-T for dermatomyositis
Saurabh Dahiya Stanford Medicine, Stanford, CA, United States
State of the art with CAR therapy in MG
Ali Habib UCI Medical Center, Orange County, CA, United States
Translational studies with T-cell engagers and CARs
Genomic determinants of resistance to anti-BCMA and GPRC5D therapies
Francesco Maura Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon
Metabolic fitness in CAR T-cells from earlier in the treatment course
Ciara Freeman Moffitt Cancer Center, Tampa, FL, United States
Coming soon
Insights into microbiome and microbial metabolites to augment CAR-T therapy
Maik Luu University of Würzburg, Würzburg, Germany
Keynote: accelerating CAR T-cell therapeutics with small molecules and CRISPR2.0 gene-edits
Michael Hudecek University of Würzburg, Würzburg, Germany
T-cell engagers for multiple myeloma
Cevostamab: What, how and when?
Rakesh Popat University College London Hospitals NHS Foundation Trust, London, United Kingdom
Teclistamab – the past was good, the future could be great!!
Tom Martin UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States
The balancing act of talquetamab
Nisha Joseph Emory University School of Medicine, Atlanta, GA, United States
Coming soon
Multi-antigen targeting with trispecific antibodies in myeloma
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Coming soon
CAR therapy for multiple myeloma
CAR T-cells in multiple myeloma: the evolving use of cilta-cel and ide-cel
Adam Sperling Dana-Farber Cancer Institute, Boston, MA, United States
Phase I/II summary of anito-cel for R/R multiple myeloma
Matthew Frigault Massachusetts General Hospital, Boston, MA, United States
Arlocabtagene autoleucel in R/R multiple myeloma
Susan Bal University of Alabama, Birmingham, AL, United States
Coming soon
BCMA CAR-T clash of the Titans: ide-cel and cilta-cel for R/R multiple myeloma
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
CAR therapy should come before T-cell engagers in multiple myeloma treatment sequencing
For
Krina Patel The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Coming soon
Against
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Different approaches to CAR production in lymphoma
Rapcabtagene autoleucel for B-cell lymphomas and the potential role of CAR-T rapid manufacturing
Julio Chavez Moffitt Cancer Center, Tampa, FL, United States
ATALANTA-1: Phase I/II trial of GLPG5101 for the treatment of R/R NHL
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Interim results: Phase II trial of zamtocabtagene autoleucel for R/R DLBCL
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
Long-term follow-up and outcomes with CARs
Long-term complications after CAR T-cell therapy
Michael Jain Moffitt Cancer Center, Tampa, FL, United States
Beyond CRS and ICANS: non-relapse mortality after CAR T-cell therapy
Kai Rejeski LMU Munich, Munich, Germany
Catch me if you can: lymphoma resistance to CAR-T immunotherapy
Marco Ruella University of Pennsylvania, Philadelphia, PA, United States
Enhancing CAR T-cell activity and persistence with CAR-enhancer therapeutics
Mohammad Rashidian Dana-Farber Cancer Institute, Boston, MA, United States
Coming soon
T-cell engagers and CARs in myeloid malignancies
Back to the bench: rethinking CAR-T for AML
Marion Subklewe LMU Hospital Munich, Munich, Germany
Allogeneic, off-the-shelf, CAR T-cells for AML
Jae Park Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Coming soon
Immunotherapy in CALR-mutated MPNs: approach with caution
Andrew Kuykendall Moffitt Cancer Center, Tampa, FL, United States
What are the current challenges with CAR-T in lymphoma and how can we address them?
Barriers: why is CAR T-cell therapy not reaching its potential in heme malignancies?
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Sequencing novel treatment options in lymphoma
Gloria Iacoboni Vall d’Hebron Institute of Oncology, Barcelona, Spain
Clinical development in B-cell malignancies: have we reached the finish or hit a wall?
Frederick Locke Moffitt Cancer Center, Tampa, FL, United States
Keynote: Building a fast-paced outpatient IEC program
Elizabeth Budde City of Hope, Duarte, CA, United States
T-cell engagers and CARs in lymphomas (part I)
Fixed-duration treatment with epcoritamab
Alexey Danilov City of Hope, Duarte, CA, United States
Bispecifics in lymphoma: moving beyond CD20 targeting
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
T-cell engagers and CARs in lymphomas (part II)
Frontline & second-line DLBCL treatments – where are we in 2025?
Matt Lunning University of Nebraska Medical Center, Omaha, NB, United States
Bispecific combinations in relapsed/refractory DLBCL
Jennifer Crombie Dana-Farber Cancer Institute, Boston, MA, United States
“Who’s on first”….Sequencing bispecifics with CAR-T in indolent lymphoma
Tycel Phillips City of Hope, Duarte, CA, United States
Coming soon
